Fexinidazole

FDA

• First-stage (hemolymphatic) and second-stage (meningoencephalitic) human African trypanosomiasis (HAT) due to T. brucei gambiensein patients 6 years of age and older who weigh at least 20 kg.
• Due to decreased efficacy observed in patients with severe second-stage HAT, fexinidazole should only be used in these patients if no other options are available.
• This drug was developed as part of the Drugs for Neglected Diseases initiative.